Immunotherapy for metastatic melanoma has a decades-long history, and the relatively recent use of checkpoint inhibitors has revolutionized treatment. Durable and sometimes complete remission of metastatic melanoma is now achievable in some patients who receive checkpoint-blocking therapy. However, it is unclear why some patients fare better than others. This review highlights several molecular indicators of response to checkpoint inhibition in metastatic melanoma, focusing on tumor programmed death ligand 1 expression, major histocompatibility complex class I expression, mutational load in the tumor, and T-cell infiltration into the tumor. In addition, clinical correlates of response, notably vitiligo and other immune-related adverse events, can potentially shed light on the mechanisms by which checkpoint blockade may achieve such great success, particularly in melanoma. The authors propose that microphthalmia-associated transcription factor-a key regulator of melanocyte survival, melanin production, and melanoma transformation-produces a molecular landscape in melanocytes and melanoma cells that can make melanomas particularly susceptible to checkpoint blockade and also can result in immune attack on normal melanocytes. Cancer 2017;123:2143-53. V C 2017 American Cancer Society.
INTRODUCTION
Once 1 of the most lethal types of cancer, metastatic melanoma can now be controlled, with long-term major responses that hopefully are cures, in significant subsets of patients using novel immunotherapies. It has been known for more than half a century that melanoma can sometimes spontaneously regress. Even at the time of those early reports, it was clear that the regression was immune-mediated 1 but unclear why regression could happen spontaneously in some patients but not in others. Starting decades ago, attempts were made to manipulate the immune system to achieve more immune-mediated regressions. Original approaches achieved only marginal success and were sometimes toxic to the patient. For example, in a decades-old strategy, bacillus Calmette-Guerin was injected as an adjuvant into a melanoma region to induce an immune response. 2 Later, high-dose interleukin 2 (IL-2) was used as a general immune activator to induce tumor killing. 3, 4 The IL-2-elicited immune response achieved a cancer response in a minority of patients, some of whom had durable responses. More recent advances have made it possible to induce a similar immune-mediated disappearance of melanoma metastases in higher fractions of patients. A more targeted approach, rather than inciting a proinflammatory milieu at the site of a tumor, takes advantage of endogenous adaptive immunity against transformed cells: the immune system is capable of carrying out cancer surveillance. Immune-checkpoint blockade has proven to be an incredibly powerful technique of co-opting the adaptive immune system to attack tumor cells. Many patients with metastatic melanoma can be saved, but the problem remains that many other patients' cancers relapse or remain refractory to immunotherapy. Just as in the early studies of immune-induced clearance of melanoma, it is largely unclear what mechanistically determines response and resistance, although some significant clues are beginning to emerge. In this review, we summarize findings on the biologic and clinical patterns underlying response to immune-checkpoint blockade.
Immune checkpoints play an important role in a healthy immune response by suppressing aberrant responses against normal cells and by down-regulating responses to chronic antigens to limit collateral tissue damage. In cancer, it is believed that costimulatory pathways-notably the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4/B7 (CTLA4/B7) pathways (summarized in Fig. 2 )-play an important role in suppressing or limiting the native immune response to tumor cells. The biology of these costimulatory pathways and their roles as immune checkpoints in cancer have been explained in depth elsewhere. [5] [6] [7] [8] Briefly, for a T cell to become active against a tumor cell, it must be educated both to recognize a foreign epitope on that cell-such as a neoantigen peptide loaded on major histocompatibility complex (MHC) class I of a tumor cell-through its Tcell receptor (TCR) and to recognize that this foreign epitope represents danger. The danger signal is conveyed through an array of costimulatory signals, 2 of which (PD-1/PD-L-1 and CTLA4/B7) are particularly important for current immunotherapy. The primary signal of a T cell comes from its TCR binding peptide-loaded MHC on a target cell or an antigen-presenting cell (APC). If the T cell expresses PD-1, and PD-1 binds its ligand PD-L1 or PD-L2 on either the APC or the potential target cell, then the interaction suppresses the T-cell's inflammatory response. The T cell can also express the costimulatory receptor cluster of differentiation 28 (CD28) (activating) or CTLA4 (CD157; repressing), both of which compete for binding with B7 on the APC or the target cell; engagement of B7 and CD28 sends an activation signal, whereas B7-CTLA4 binding represses T-cell activity. The binding affinity of CTLA4 is greater than that of CD28 for B7, so the repressive signal generally outweighs the activation signal when both CTLA4 and CD28 are expressed on the T cell and are competing for engagement with B7.
Antibodies against PD-1, PD-L1, and CTLA4 can block these checkpoints, lifting a set of brakes that governs immune tolerance, thereby releasing an immune response to melanoma cells that was otherwise suppressed. When these immune-checkpoint inhibitors are successful, they can achieve remission or even a cure, and approximately 25% to 50% of patients with metastatic malignant melanoma achieve progression-free survival. 9 It remains largely unclear why some patients respond but others do not. The long tail of survivors on the Kaplan-Meier curves is even more intriguing: Why do some patients not only respond but achieve complete, durable remissions, whereas others exhibit only partial responses? To date, multiple molecular and clinical biomarkers have been proposed as correlates of immunotherapy success, but the biologic and molecular mechanisms underlying why some melanomas respond to treatment and others do not remain incompletely understood. Molecular, cellular, and clinical correlates of response have been described and, together, reflect an intertwined system of immune regulation of cell killing. Moreover, melanocytes and melanoma cells are subject to a delicate balance between immune recognition of tumor cells and the ingrained transcriptional program that encourages melanocyte survival even after DNA damage.
MOLECULAR CORRELATES OF MELANOMA RESPONSE TO CHECKPOINT BLOCKADE Multiple molecular correlates of melanoma response to immune-checkpoint inhibition have been proposed. These correlates are useful not only as biomarkers but also as harbingers of the underlying biologic mechanisms that make some melanomas susceptible to immunecheckpoint-blocking therapy, potentially providing clues for cotreatment options that might enhance the efficacy of checkpoint blockade.
Tumor PD-L1 Expression
On the basis of early knowledge of the PD-1/PD-L1-inhibitory pathway, it was hypothesized that successful anti-PD-1/anti-PD-L1 therapy would mechanistically rely on the expression of PD-L1 in tumor cells or APCs. In support of this hypothesis, it was observed that mouse tumors expressing PD-L1 resisted immune detection and destruction; conversely, lack of PD-1 or treatment with an anti-PD-L1 antibody prevented tumor growth. 10 Blocking this pathway would only work, in theory, if the tumor already was evading immune surveillance using the PD-1/ PD-L1 signal. An early clinical trial of anti-PD-1 therapy measured PD-L1 expression on tumor cells and suggested that PD-L1 expression in tumor biopsies correlated with response to therapy. 11 Since that relatively early study, multiple groups have followed with various results on the correlation of PD-L1 expression for the success of PD-1-blocking/PD-L1-blocking immunotherapy. Some analyses have indicated that PD-L1 is not a biomarker of response to melanoma. 12 Those discrepant conclusions may stem from differences in experimental protocols: for example, the threshold of PD-L1 expression in determining whether a tumor is PD-L1-positive; distinguishing between PD-L1 expression on tumor cells, stromal cells, and infiltrating immune cells (by costaining for PD-L1 and cell type markers); or the number of different tumor locations examined for PD-L1 expression in each patient.
A recent meta-analysis of anti-PD-1 and anti-PD-L1 therapy (nivolumab and pembrolizumab) examined 20 trials, including 7 patients with melanoma, and reported that the overall response was significantly higher in tumors that were positive for PD-L1. Notably, the study indicated that the threshold for calling a tumor positive for PD-L1 had an impact on study conclusions (ie, tumor response correlated with PD-L1 expression was called at a 5% cutoff but not at a 1% cutoff), providing 1 possible explanation for the differing conclusions across studies. 13 Although T cells can receive the PD-L1 signal from multiple cell types-notably both APCs and tumor cells-the particular PD-L1-positive cells within the tumor microenvironment may influence the biology of checkpoint blockade. Some investigators have observed that only PD-L1 expression on infiltrating immune cells, and not on tumor cells, is correlated with response in melanoma (and other cancers).
14 In some patients who initially respond to anti-PD-1 therapy, melanoma cells express PD-L1 before therapy; however, upon relapse, melanoma cells are PD-L1-negative; in contrast, in the same study, macrophages and stromal cells did express PD-L1 during relapse. 15 Thus, although cell type may influence PD-1-PD-L1 interactions and the impact of checkpoint blockade, the precise relation between cell type-specific PD-L1 expression and response to checkpoint blockade remains unclear.
Apart from these experimental considerations in the link between PD-L1 expression and response to checkpoint blockade, there may be molecular considerations that complicate the direct correlation between PD-L1 and response. The immunologic tumor microenvironment may play a role in regulating tumor PD-L1 expression. Interferon c (IFN-c) secreted by infiltrating lymphocytes is associated with the up-regulation of PD-L1 in melanoma cells. 16 Melanomas can evolve to be refractory to this IFN-c signaling, reducing the efficacy of PD-1 or PD-L1 blockade. In melanomas that initially responded to anti-PD-1 therapy, it was observed that Janus kinase 1 (JAK1) and JAK2 loss-of-function mutations arose in subsequently recalcitrant melanomas. 15 The loss of functional JAK2 prevented signaling from IFN-c, including failure to induce phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and PD-L1, resulting in unchecked growth. 15 Even if the tumor cells have evolved away from the PD-L1 immune-evasion mechanism, it is still feasible that anti-PD-L1/anti-PD-1 treatment could work by blocking T-cell exhaustion elsewhere, such as in a lymph node, allowing increased antitumor immunity. The problem with this model is that PD-L1-negative tumors have probably evolved an alternative mechanism for evading immune surveillance, so T cells activated elsewhere with PD-1/PD-L1 blockade would need to surpass the other mechanism(s) of immune evasion upon entering the tumor. This model and the IFN-c signaling observations suggest that PD-L1 expression may be considered a biomarker of many processes in the tumor, which may help explain the frequent but nonubiquitous correlation between positive PD-L1 tumor status and response to checkpoint blockade.
PD-L1 expression is not only relevant to anti-PD-1 and anti-PD-L1 therapy. In anti-CTLA4 therapy (combined with radiation), resistance is associated with PD-L1 up-regulation, suggesting that tumors circumvent CTLA4 blockade by evolving to use the PD-1-PD-L1 immune-evasion pathway. In a mouse model, concomitant use of anti-CTLA4, radiation, and anti-PD-L1 or anti-PD-1 therapy improved survival substantially, 17 further supporting the model that tumors evolve to use whatever immune-evasion techniques are available to them, sometimes involving PD-L1 up-regulation and other times requiring PD-L1 down-regulation, with up-regulation of alternative immune-evasion pathways.
Tumor MHC Expression
T cells recognize and kill infected or foreign cells when they recognize peptide bound to the MHC. CD8-positive T cells recognize the MHC class I normally present on all cells, which presents peptides derived from intracellular protein processing ( Figs. 1 and 2 ). CD4-positive T cells recognize the MHC class II normally present on APCs of the immune system, which sample antigens from their environment, cleave them, and present these extracellular peptides.
Down-regulating MHC I would be 1 tumor survival strategy that could feasibly detract from the efficacy of checkpoint blockade. Without MHC I, neoantigens from the tumor cells could not be presented, so tumor-specific T cells would have difficulty recognizing a target epitope, let alone binding a costimulatory ligand. In an early study of immunotherapy using tumor-infiltrating, CD8-positive T cells, some melanoma biopsies revealed a lack of b 2 microglobulin (b2M), which is a necessary molecular component of MHC I. Patients with these MHC I-deficient melanomas did not respond to T-cell-based immunotherapy, but CD8-positive T cells were capable of killing them in culture once b2M was restored. 18 Since then, others have validated the finding that melanomas can evade tumor-infiltrating lymphocytes through loss of MHC I expression. 15, 19, 20 In particular, b2M mutations, resulting in loss of MHC I expression, have been correlated with acquired resistance to anti-PD-1 therapy after initial response. 15 How abundant these mechanisms are and whether heterozygous loss-of-function mutations can dominantly affect downstream biologic functions remain to be determined. In contrast, some analyses have failed to observed MHC I down-regulation on tumor cells and have reported no correlation with response. 12 Some form of MHC I dysregulation is relatively common in melanoma cell lines, but the phenotype is often reversible in culture using IFN-c treatment. 21 Molecularly, IFN-c induces MHC I expression through phosphorylation of STAT1. It has been reported that melanoma cell lines lose the capability to signal downstream of IFN-c, thus losing IFN-c-mediated MHC I induction. 22 These results suggest that down-regulation of MHC I, potentially caused by the loss of IFN-c-signaling machinery, could be 1 mechanism-but likely not the sole mechanism-of immune evasion. The mechanism highlights particular resistance to checkpoint blockade, which relies on TCR binding of peptide-MHC complexes on tumor cells. Without proper peptide presentation, T-cellmediated cytotoxicity is difficult, but natural killer (NK) cells have the ability to kill cells that lack MHC I; in culture, NK cells can kill melanoma cell lines that lack MHC I, 23 suggesting future potential synergies between T-cellbased and NK cell-based immunotherapy approaches.
It is noteworthy that some melanomas aberrantly express MHC II-some express human leukocyte antigen (HLA)-antigen D related (HLA-DR), HLA protein/ peptide-antigen receptor (HLA-DP), and HLA cellsurface receptor protein (HLA-DQ), whereas some only express a subset of these 3 HLAs. 21 Even in some melanoma cell lines without constitutive MHC II expression, Figure 1 . The microphthalmia-associated transcription factor (MITF) pathway is illustrated. The sun's ultraviolet light (UV) damages DNA in cells in the skin, particularly keratinocytes and melanocytes. In keratinocytes, DNA damage triggers p53, which induces expression of proopiomelanocortin (POMC). POMC is cleaved to produce a-melanocyte-stimulating hormone (aMSH), a hormone that is released from the keratinocyte. Melanocortin 1 receptor (MC1R), a receptor on melanocytes, binds aMSH, causing activation of protein kinase A (PKA) through production of cyclic adenosine monophosphate (cAMP). PKA then phosphorylates cAMP-responsive element-binding protein (CREB), activating it as a transcription factor that up-regulates the expression of MITF, a melanocyte lineage-specific transcription factor. MITF, in turn, activates multiple genes involved in pigmentation and cell survival, allowing continued melanin production despite UV-induced DNA damage. Because the melanocyte has sustained DNA damage, some proteins produced downstream of MITF may harbor mutations. Proteins expressed downstream of MITF are degraded by the proteasome and epitopes, including those with mutations, are presented on major histocompatibility complex class I (MHCI).
MHC II could be induced with IFN-c treatment. 21 Aberrant expression of the class II transactivator (CIITA), through a mechanism normally active in B cells, induces MHC II expression in melanomas. 24 HLA-DR expression has been correlated with response to anti-PD-1 or anti-PD-L1 therapy. 12 
Mutational Load in the Tumor
Cutaneous melanocytes are unusually long-lived considering the large amount of radiation they withstand and the concomitant mutations they accumulate. Melanocytes are subject to a large amount of ultraviolet (UV) radiation from sunlight, which causes the signature dipyrimidine mutations that accumulate in the melanocyte genome. 25, 26 On average, melanomas have a greater mutational load than other cancers, but the mutational load is also highly variable among melanomas. 27 A high mutational load has been correlated with melanoma response to anti-CTLA4 therapy. 28 In line with this observation, several types of tumors with mismatch-repair defects, including melanoma, respond better to anti-PD-1 therapy, 29 presumably because of their weakened ability to repair DNA damage. It has also been observed that cancers associated with high mutational load (eg, melanomas or lung cancers) tend to respond better to immunecheckpoint inhibition than other tumor types (eg, colorectal cancer). 29 Mechanistically, higher mutational load in melanomas may increase the efficacy of checkpoint inhibition through the production and presentation of immunogenic neoantigens, allowing T-cell recognition. Indeed, a case study of successful melanoma treatment with anti-CTLA4 revealed that expanded T-cell populations existed in which the TCRs were specific for neoantigens Figure 2 . T-cell recognition of melanocyte antigens and neoepitopes is illustrated. When microphthalmia-associated transcription factor (MITF) is induced (see Fig. 1 ), it causes the up-regulation of many genes relevant for pigmentation and cell survival. Because of accumulated ultraviolet (UV) radiation-induced DNA damage, some of these genes likely harbor mutations. The proteasome system degrades proteins in the cell, allowing presentation of endogenous antigens on major histocompatibility complex class I (MHCI). Thus, MHC will present some neoepitopes. In addition to melanocyte-intrinsic survival factors, the melanocyte must survive cluster of differentiation 8 (CD8) (a transmembrane glycoprotein) T-cell recognition of these neoepitopes through T-cell receptor (TCR) binding to peptide MHC and a cytotoxic response. Costimulatory molecules, notably the B7-CD28/cytotoxic T-lymphocyte-associated protein 4 (B7-CD28/CTLA4) and programmed cell death ligand 1/programmed cell death 1 (PD-1/PD-L1) pathways, help dictate whether the CD8 T cell will respond by killing the melanocyte or becoming tolerant upon TCR engagement of a foreign epitope. PD-1 and CTLA4 send suppressive, tolerizing signals, whereas CD28 engagement signals CD8 activation of a cytotoxic response. Checkpoint inhibitors-notably anti-PD-1, anti-PD-L1, and anti-CTLA antibodies-encourage the CD8 T cell to kill a target cell when its TCR engages a peptide-MHC complex perceived as foreign. Once an immunogenic epitope is recognized, epitope spreading can occur, leading to activation against other antigens coexpressed on the melanocyte. Asterisks (*) indicate the main sites of known resistance to immunotherapy. Melanomas can evolve to evade immune recognition of their neoepitopes by down-regulating MHC class I, often through mutations in b 2 -microglobulin (b2M). In addition, mutations in the Janus kinase 1-signal transducer and activator of transcription 1 (JAK-STAT) pathway prevent interferon g (IFN-g)-mediated up-regulation of PD-L1 and MHC class I.
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Cancer generated through somatic mutation in melanoma. 30 Some have speculated that mutational load itself is not a driver of successful immune recognition; instead, mutational load may simply be correlated with the generation of specific epitopes, which serve as the key flags for immune attack when checkpoint inhibitors are administered. For example, in 1 study, although response to anti-CTLA4 therapy correlated with mutational load, it correlated even more closely with the presence of a set of signature tetrapeptides. These tetrapeptides themselves were associated with a high mutational load. It was observed that the tetrapeptides were similar to microbial antigens, potentially explaining their ability to predict immune destruction of melanoma after anti-CTLA4 therapy. 31 Although the similarity of neoantigens to microbial epitopes that drive effective anti-CTLA4 response is an intriguing and elegantly intuitive hypothesis, it has not been replicated in subsequent studies. 28 For example, in another study, although the load of potentially immunogenic neoantigens was correlated with response to anti-CTLA4, there were no clear patterns of repeated neoantigens across responders that distinguished them from nonresponders. 28 Taken together, the correlation between mutational load and response to checkpoint blockade is fairly well established, whereas it is still unclear whether these somatic mutations produce a set of signature neoepitopes that causally drive response to therapy. It is also uncertain whether there may exist recurrent (eg, microbial-related) neoantigens/epitopes that function for tumor recognition and killing across different patients.
The correlation between mutational load and response to checkpoint inhibition is complicated by dependence on the proper protein processing and presentation of MHC I in order for mutational burden to have any immunologic significance. Furthermore, if a neoepitope is presented, then it is possible for tumors to evade immune attack by presenting tolerance signals (for example, PD-L1 up-regulation after anti-CTLA4 therapy). Thus, each of these molecular correlates of response to checkpoint blockade is linked to the others.
If increased mutational load does indeed cause greater response to checkpoint blockade, then the concomitant use of radiation may serve as a potential enhancer of immunotherapy efficacy. 32 The phenomenon of systemic tumor clearance that can be induced by local radiation is termed the "abscopal" effect. The abscopal effect has been documented after radiation in several cancers; a melanoma case report documented that the combination of anti-CTLA4 therapy followed by radiation of 1 melanoma lesion resulted in regression of lesions that were not irradiated, probably because of immune activation against antigens in the irradiated tumor that were shared with unirradiated metastases. 33 The underlying biologic mechanism for the abscopal effect was further investigated in a mouse model with bilateral tumors. Combined anti-CTLA4 therapy with unilateral radiation was more effective in causing regression of the unirradiated tumor than anti-CTLA4 therapy alone. 17 Radiation and checkpoint blockade appear to work synergistically, with anti-CTLA4 decreasing regulatory T-cell infiltration in the tumor and radiation increasing TCR diversity in the infiltrating T cells. The addition of anti-PD-L1 increased the number of infiltrating CD8-positive T cells; triple therapy with combined radiation, anti-CTLA4, and anti-PD-1/anti-PD-L1 caused even more profound tumor regression and survival. 17 Although the immunologic mechanism and case reports are intriguing, evidence does not yet conclusively establish that the abscopal effect, and subsequent tumor regression, can be induced by a combination of checkpoint blockade and radiation. In 1 recent study, radiation was tolerated with ipilimumab, although the benefit of dual therapy is not yet well defined. 34 
T-Cell Infiltration in the Lesion
If response to checkpoint blockade depends on melanoma tumor expression of PD-L1 and MHC I, with neoepitopes loaded on MHC, then it follows that T cells must be present in the tumor to recognize these molecular features. Thus, T-cell infiltration into a tumor has been measured as a correlate of success for checkpoint blockade. In biopsies from patients with melanoma before treatment with anti-PD-1, during response, and during relapse, CD8-positive T cells were observed inside the tumor only during response to therapy; whereas, before therapy and during relapse, CD8-positive T cells were relegated to the tumor margins. 15 Assessments of T-cell infiltration are complicated by the interplay between T cells and other correlates of response, such as MHC and the PD-1/PD-L1 interaction. In a mouse experiment testing vaccination with irradiated melanoma cells plus anti-PD-1/anti-PD-L1 and/or anti-CTLA4 checkpoint blockade, treatment with only 1 checkpoint inhibitor induced T-cell infiltration early on but resulted in subsequent up-regulation of the other checkpoint pathway, preventing further immune attack of the tumor. 35 Measuring T-cell infiltration is also complicated by various T-cell roles and the cytokines that shape these roles. In the mouse model, a combined treatment strategy enhanced T-cell infiltration into the tumor over a prolonged period, with a notable increase in the effector T-cell to regulatory T-cell ratio inside the tumor. 35 Cytokines in the tumor microenvironment may help shape this response, including IFN-c and tumor necrosis factor (TNF)-a secreted by infiltrating T cells. 35 This study illustrates the complexity of assessing any single molecular correlate of melanoma response, because checkpoint ligand/receptor expression, MHC expression, epitope presentation, and T-cell infiltration are all interrelated. Although there is a compelling mechanistic explanation for T-cell infiltration to correlate with response to checkpoint blockade, in some studies, CD8-positive Tcell infiltration does not correlate with response. 29 It is difficult to determine which of these conclusions reflects a meaningful biologic correlate or, instead, is an artifact of an underlying network of cellular interactions. For example, infiltrating CD4-positive T cells are strong TNF producers, which, in an environment high in IFN-c, suppresses CD8-positive T-cell reactivity to melanoma. 36 Measurements of "T-cell infiltration" are very likely sensitive to the types and activity of T cells assessed. Similarly, infiltrating T cells produce IFN-c, which causes upregulation of PD-L1, so measuring PD-L1 and T-cell infiltration are not independent biologic variables. 16 In another example, 1 study indicated that PD-L1 expression, mismatch-repair deficiency, and mutation load were correlated with each other; however, in that study, PD-L1 expression did not correlate with response to checkpoint inhibition. 29 The microenvironment produced by the tumor-by infiltrating T cells, by innate immune cells, or by sentinel cells at the tumor site-likely plays an enormous role in the efficacy of T cells locating and killing tumor cells. Checkpoint inhibition can surely alter the tumor microenvironment by changing the balance of tumor tolerance and rejection. Many more factors also contribute to this environment. Clinically, for example, the combination of intratumoral injection of IL-2 with anti-CTLA4 appeared to produce responses in a phase 1 trial. 37 In summary, each of these molecular and cellular markers is linked to the others, and all have been correlated to some extent with checkpoint-inhibition response. Although PD-L1 expression, MHC expression, and mutational load all certainly play a part in the molecular mechanism underlying the success or failure of checkpoint blockade, they are linked in a network that is not yet fully understood and likely involves many other components of immune signaling. Further work is required to disentangle these and many other molecular and cellular variables to elucidate the pathways that particularly predict response to therapy.
CLINICAL CORRELATES OF RESPONSE TO CHECKPOINT BLOCKADE: AUTOIMMUNITY AND VITILIGO
Although the cellular and molecular correlates of response to checkpoint blockade discussed above suggest important biologic mechanisms for immune recognition and destruction of tumor cells after checkpoint-blocking therapy, clinical observations in patients who receive these treatments may also offer clues to successful therapy. In particular, autoimmunity has been well documented in patients who receive treatment with checkpoint inhibitors. Of particular interest, vitiligo often accompanies immunotherapy in patients with melanoma and even correlates with tumor regression after checkpoint blockade.
Immune-related adverse events may occur during either anti-CTLA4 or anti-PD-1/anti-PD-L1 therapy. 38, 39 In multiple types of cancers, the occurrence of immunerelated adverse events correlates with response to checkpoint blockade. 40 In melanoma, patients who respond well to checkpoint blockade and other types of immunotherapy often experience vitiligo. [41] [42] [43] Vitiligo is a much more common adverse event in melanoma immunotherapy compared with immunotherapy for other solid tumors. 44, 45 Other immune-mediated cutaneous complications have also been described during checkpoint-inhibitor therapy. 45 Anti-PD-1 not only causes vitiligo but can also cause cutaneous autoimmune destruction similar to toxic epidermal necrolysis. 46 Bullous pemphigoid has been reported in the absence of melanoma response to anti-PD-1 therapy. 47 Most provocatively, in a clinical trial for anti-PD-1, rash and vitiligo-but not other immune-related adverse events-were correlated with the survival of patients with metastatic melanoma. 48 Previously, vitiligo was correlated with metastatic melanoma response to IL-2 and other types of immunotherapy. 44, 49 In addition to vitiligo secondary to checkpoint inhibition, hapten-associated depigmentation has been clinically described. Imiquimod, a toll-like receptor 7 agonist, is used topically to treat human papillomavirus and basal cell carcinoma, but local depigmentation has been observed after treatment. 50, 51 Monobenzone causes haptenization of melanocyte proteins, inducing an immune response against melanocytes that causes both vitiligo-like depigmentation and an attack on melanoma cells. 52 These observations suggest that prompting an immunologic attack on skin epitopes, through either checkpoint blockade or these other topically applied immune activators, prompts a dual attack on cancer cells and healthy melanocytes.
When vitiligo occurs in the absence of cancer immunotherapy, it is most commonly mediated by an autoimmune attack on melanocytes and presents clinically as progressively spreading, depigmented lesions. Immunostaining of vitiligo lesions has revealed a CD8-positive T cell, the Th17 cell, and a dendritic cell infiltrate with a loss of regulatory T cells (reviewed by Oiso et al 53 ). Genomewide association studies have revealed several genes that may be linked to vitiligo, including MHC class I and II, part of the inflammasome, and genes involved in regulatory T cells (reviewed by Oiso et al 53 ). Unsurprisingly, many of these pathways are similar to those highlighted in the molecular correlates of melanoma response to checkpoint blockade. It might be argued that these pathways are simply fundamental tenets of any immune response. Alternatively, the dual clinical and mechanistic correlation between vitiligo and response to checkpoint blockade may shed light on the mechanisms of successful immune attack of melanoma cells and incidental attack of normal melanocytes.
A mouse model has been developed that, in some ways, mimics the dual attack on melanoma cells and healthy melanocytes in the context of immune-checkpoint blockade or topical hapten treatment. The pmel-1 CTLA-4 2/2 mouse model is deficient in CTLA-4 and has T cells with a transgenic TCR that is reactive to melanoma. 54, 55 Although these mice survive longer than CTLA-4 2/2 mice without a manipulated T-cell repertoire, they do develop autoimmune vitiligo. 55 These results suggest a skin-targeted autoimmune attack when loss of an immune checkpoint is combined with melanoma-specific T cells. The results demonstrate a compelling mouse-model parallel to anti-PD-1, anti-PD-L1, or anti-CTLA4 treatment in humans: effective treatment is thought to rely on the presence of tumor-specific T cells, and efficacy against melanoma is correlated with the development of vitiligo. In parallel, in a melanoma clinical trial of adoptive transfer of melan A (MART-1)-specific, CD8-positive T cells, inflammation was induced at pigmented lesions with the infiltration of anti-MART-1 T cells; loss of melanocytes and vitiligo followed. 56 Immune attack on healthy melanocytes upon melanoma sensitization also appears to occur in humans. Two observations have been made in humans, in which topical treatment using contact sensitizers on a melanoma metastasis, combined with anti-PD-1, resulted in systemic tumor responses as well as vitiligo symptoms. 57, 58 CHECKPOINT-BLOCKADE RESPONSE AND VITILIGO IN THE CONTEXT OF THE MELANOCYTE LINEAGE TRANSCRIPTIONAL LANDSCAPE The downstream transcriptional effects of microphthalmia-associated transcription factor (MITF), an oncogene and a master transcriptional regulator of the melanocyte lineage, may contribute to the connection between melanoma response to immune-checkpoint inhibition and the vitiligo phenotype. Normal melanocytes survive a large accumulation of DNA damage, which is a necessary adaptation to prevent melanocyte loss after UV exposure and thus retain tanning capability after DNA damage. Melanocyte survival hinges on the downstream effects of MITF, the M isoform of which (MITF-M) is a melanocyte lineage-specific transcription factor (reviewed by Hsiao and Fisher 59 ) . MITF is required for melanocyte development, as evidenced by MITF-mutant mice exhibiting phenotypes that include white fur, because of a lack of melanocyte development or survival. 59 Melanocyte survival after UV and DNA damage is hard-wired into the melanocyte lineage. In the UVstimulated pigmentation response, epidermal melanocytes respond to signals from overlaying keratinocytes. When keratinocytes experience DNA damage because of UV radiation, tumor protein p53 (p53) activates the expression of proopiomelanocortin, 60 from which amelanocyte-stimulating hormone (a-MSH), a short peptide hormone, is proteolytically cleaved and secreted by the keratinocyte. Secreted a-MSH subsequently docks on a melanocortin 1 receptor (MC1R) of a nearby melanocyte. MC1R, a G-protein-coupled receptor, stimulates adenylate cyclase to catalyze the synthesis of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP), allowing the phosphorylation of cAMP response element binding protein (CREB) and activating MITF-M expression (Fig. 1) . MITF-M then acts as a wide-ranging transcription factor (reviewed by Lo and Fisher 61 ). MITF-M has multiple target genes that are important in both the tanning response and the survival or proliferation of melanocytes. For example, B-cell lymphoma 2 (BCL2), which is known for its roles in regulating apoptosis, is a downstream target of MITF that is necessary for melanocyte survival. 62 MITF has also been characterized as an oncogene driving melanoma-genesis (reviewed by Levy et al 63 ) . MITF is also mutated at a recurrent position in certain familial melanomas. 64 It is amplified in 5% to 20% of sporadic melanomas, but not in benign nevi. 65 MITF amplification in the context of melanoma is associated with decreased survival 65 but has not been assessed for a correlation with response to checkpoint blockade. The MITF-pigmentation pathway is also linked to the risk of melanoma in red-headed individuals. The phenotype of red hair and an inability to tan is caused by loss-offunction polymorphic variants in MC1R, the receptor for a-MSH that allows signaling from keratinocytes to melanocytes and, eventually, activation of MITF expression (Fig. 1) . In addition to the lack of dark UV-shielding eumelanin, these individuals have an increased risk of melanoma independent of UV exposure that is thought to be related to pro-oxidant roles of red/blond pheomelanin pigment, 66 and their melanomas have higher numbers of both UV-associated and non-UV-associated mutational loads. 67 The finding of UV-independent melanoma risk among MC1R variants (redheads) recently was corroborated in humans. 68 It is noteworthy that the regulatory role of MITF involves inducing the transcription of many genes important in pigment production and the maintenance of the melanocyte, both in melanoma and in normal cells. After immune-checkpoint therapy, the immune system likely targets epitopes within genes downstream of MITF (Fig.  2) . Some of these MITF-regulated genes may contain tumor-specific neoantigens, and others may represent melanocyte lineage-specific "wild-type" antigens. Activation of the immune system against MITF-associated epitopes-some recognized as foreign because of somatic mutation and others recognized because of epitope spreading-results in destruction of melanoma cells, sometimes with collateral destruction of melanocytes in the process. Consistent with this mechanism, it has been demonstrated that antibodies to similar antigens in melanoma and normal melanocytes account for melanomaassociated vitiligo. 69 
CONCLUSIONS: LINEAGE-SPECIFIC PATHWAYS MODULATING IMMUNOTHERAPY RESPONSES
The necessary role of MITF in the normal melanocyte lineage and in melanomas probably is not incidental to the observation that melanoma tends to respond well to checkpoint blockade. MITF has dual complementary and critical roles in melanocytes: driving production of melanin and promoting survival after skin UV exposure. Indeed, the original signal that drives MITF is UVinduced DNA damage through p53 (Fig. 1) . The role of MITF in maintaining a functional, melanin-producing melanocyte population after UV radiation likely overrides immunologic and cell-intrinsic factors that, in other cells, could lead to cell death when DNA damage and mutations are sensed. Thus, when immunotherapy is successful, immune cells override MITF control of melanocyte survival. To date, the intersections between MITF and immune regulation are still incompletely characterized. There must be a delicately balanced regulation between MITF and the immune system that allows MITF to function as a melanocyte-lineage promoter, even in the context of large mutational burden, 70 protected from immune surveillance but somehow allowing the immune system to limit cancerous transformation (Fig. 2) . When this balance is interrupted, melanoma results. When the immune system is prompted to recognize melanoma antigens, in the context of checkpoint blockade, the balance is disrupted in the opposite direction. The immune attack sometimes destroys normal melanocytes, which, like melanoma, present melanocyte-specific epitopes-many of them likely in genes downstream of MITF-possibly including neoantigens resulting from accumulated UV damage. We hypothesize that, under this mechanism, checkpoint blockade unleashes the immune system on previously protected melanocytes, producing vitiligo.
The molecular and cellular correlates of melanoma response to checkpoint blockade likely reflect players in the immune balance with melanocyte survival. PD-L1 expression, MHC expression, mutational load, and Tcell infiltration are highlighted here, but each of these markers is intertwined with the others. The immune system's interconnected pathways of regulation, combined with the regulation of melanocyte survival by MITF, should allow for immune tolerance and survival of normal melanocytes, as they accumulate DNA damage, and also potentially for immune attack of transformed melanocytes. The observations that some patients spontaneously clear melanoma and that some are cured after broad immune activation with high-dose IL-2 therapy suggest that these immune-melanocyte relations are exceedingly finely tuned. Checkpoint inhibition pushes the balance in the direction of immune activation, which allows tumor killing, as well as normal tissue killing, more in the skin than elsewhere in the body. Hence, melanoma is particularly susceptible to checkpoint inhibition, and vitiligo sometimes results. Further work is required to understand the regulatory network between melanocytes and the immune system that, in most cases, succeeds in protecting against melanoma while retaining melanocytes for the tanning response. Clinical entities, such as metastatic melanoma of unknown primary origin, in which a presumed cutaneous primary lesion has been spontaneously destroyed by immune attack, may represent an example of this phenomenon in patients. Understanding how immune regulation intersects with the MITF pathway may further elucidate the determinants of a melanoma that portend susceptibility versus resistance to checkpoint-inhibitor therapy.
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